tiprankstipranks
Trending News
More News >
Trajan Group Holdings Ltd (AU:TRJ)
:TRJ
Australian Market
Advertisement

Trajan Group Holdings Ltd (TRJ) AI Stock Analysis

Compare
6 Followers

Top Page

AU

Trajan Group Holdings Ltd

(Sydney:TRJ)

Rating:48Neutral
Price Target:
AU$0.50
▼(-32.43%Downside)
Trajan Group Holdings Ltd faces significant financial and operational challenges, as indicated by declining revenues and profitability pressures. The technical analysis shows no strong momentum, and the valuation is unattractive due to negative earnings. The company's focus should be on improving its financial health to enhance stock performance.

Trajan Group Holdings Ltd (TRJ) vs. iShares MSCI Australia ETF (EWA)

Trajan Group Holdings Ltd Business Overview & Revenue Model

Company DescriptionTrajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.
How the Company Makes MoneyTrajan Group Holdings Ltd generates revenue through the sale of its precision consumables and scientific instruments. The company's key revenue streams include direct sales to laboratories and research facilities, partnerships with scientific and healthcare organizations, and distribution agreements with global distributors. Trajan's growth is further supported by continuous innovation in product development and strategic acquisitions that expand its product offerings and market reach. The company also benefits from long-term relationships with clients in the health, environment, and food sectors, which demand consistent and high-quality analytical solutions.

Trajan Group Holdings Ltd Financial Statement Overview

Summary
Trajan Group Holdings Ltd is experiencing financial challenges, with declining revenues and profitability pressures. The balance sheet shows moderate leverage, but net losses have negatively impacted equity metrics. Cash flow generation is strained, indicating potential liquidity risks. Improvement is needed in profitability and operational stability.
Income Statement
45
Neutral
The company experienced a decline in revenue in the most recent year, dropping from $162.2M to $155M. Gross profit margin decreased significantly from previous years, indicating cost pressures or reduced pricing power. The net profit margin turned negative, reflecting a loss position, which is concerning for profitability. The EBIT and EBITDA margins also worsened, further highlighting operational challenges.
Balance Sheet
60
Neutral
The balance sheet shows moderate stability with a debt-to-equity ratio of 0.55 in 2024, indicating manageable leverage but a decrease from 2023. Stockholders' equity decreased, negatively affecting the equity ratio. However, the company's return on equity turned negative due to net losses, which is a notable downside.
Cash Flow
55
Neutral
Operating cash flow showed slight stability, but the free cash flow decreased from the previous year. The operating cash flow to net income ratio suggests that cash generation is better than accounting income, which is a positive aspect. However, the overall cash flow situation is under pressure due to declining free cash flow, indicating potential liquidity risks.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue155.02M162.15M107.57M76.57M71.85M
Gross Profit59.75M22.93M42.63M28.48M5.86M
EBITDA-20.36M14.86M5.14M3.46M3.26M
Net Income-25.33M1.89M1.70M1.88M2.62M
Balance Sheet
Total Assets188.00M229.04M206.78M99.38M44.37M
Cash, Cash Equivalents and Short-Term Investments11.24M11.04M13.16M51.72M4.79M
Total Debt56.16M61.30M66.18M17.02M14.97M
Total Liabilities85.15M99.51M90.27M33.30M26.63M
Stockholders Equity102.85M129.53M116.51M66.08M17.74M
Cash Flow
Free Cash Flow6.43M998.00K-1.28M8.34M964.00K
Operating Cash Flow9.47M9.55M2.13M9.45M1.76M
Investing Cash Flow-3.04M-8.55M-116.38M402.00K-797.00K
Financing Cash Flow-6.40M-3.36M74.69M36.81M-236.00K

Trajan Group Holdings Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.74
Price Trends
50DMA
0.78
Negative
100DMA
0.81
Negative
200DMA
0.93
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
48.96
Neutral
STOCH
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRJ, the sentiment is Positive. The current price of 0.74 is above the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.78, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:TRJ.

Trajan Group Holdings Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUAHC
78
Outperform
AU$127.51M12.8223.38%63.10%290.00%
AUEZZ
76
Outperform
AU$108.97M11.2445.86%1.73%71.65%152.89%
65
Neutral
¥347.74B11.06-2.99%2.56%11.77%-10.16%
AUTRJ
48
Neutral
AU$112.76M-24.66%0.70%-1600.91%
AUSHG
48
Neutral
AU$102.58M
AUCYC
45
Neutral
AU$121.69M-35.20%4.68%-155.42%
AUALA
40
Underperform
AU$124.80M-85.35%315.11%51.16%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:TRJ
Trajan Group Holdings Ltd
0.74
-0.23
-23.71%
AU:AHC
Austco Healthcare Limited
0.35
0.13
59.09%
AU:CYC
Cyclopharm Limited
1.10
-0.54
-32.93%
AU:SHG
Singular Health Group Ltd
0.34
0.24
240.00%
AU:EZZ
EZZ Life Science Holdings Ltd.
2.31
0.06
2.67%
AU:ALA
Arovella Therapeutics Limited
0.10
-0.06
-37.50%

Trajan Group Holdings Ltd Corporate Events

Trajan Group Holdings Ltd Announces Cessation of Securities
Jun 27, 2025

Trajan Group Holdings Ltd has announced the cessation of 88,635 securities due to the lapse of conditional rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This announcement may impact the company’s issued capital and could have implications for stakeholders regarding the company’s securities management.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Trajan Group Holdings Navigates Geopolitical Challenges with Strategic Resilience
May 29, 2025

Trajan Group Holdings Limited has announced its operational update, highlighting its resilience and agility in navigating the shifting geopolitical landscape. Despite challenges such as new tariffs and reduced US government funding, Trajan maintains its FY25 revenue guidance, expecting growth of at least 3% over the prior year. The company is expanding its regional manufacturing capabilities to mitigate risks and enhance supply chain resilience, while also deepening relationships with global customers. Although there is some risk to achieving nEBITDA guidance due to margin performance, Trajan remains confident in its strategy and ability to manage through complexity.

The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025